Grandfield & Dodd LLC Buys 1,149 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Grandfield & Dodd LLC grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 93.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,373 shares of the biopharmaceutical company's stock after purchasing an additional 1,149 shares during the quarter. Grandfield & Dodd LLC's holdings in Alnylam Pharmaceuticals were worth $558,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Huntington National Bank boosted its position in shares of Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 45 shares in the last quarter. Hollencrest Capital Management acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $29,000. R Squared Ltd bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $33,000. Washington Trust Advisors Inc. acquired a new stake in Alnylam Pharmaceuticals in the third quarter worth $42,000. Finally, True Wealth Design LLC increased its stake in Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 153 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the transaction, the executive vice president now owns 12,881 shares in the company, valued at $3,240,344.36. This trade represents a 10.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO Pushkal Garg sold 1,548 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $251.67, for a total value of $389,585.16. Following the completion of the transaction, the chief marketing officer now owns 11,989 shares of the company's stock, valued at approximately $3,017,271.63. This trade represents a 11.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 72,986 shares of company stock valued at $20,397,849 over the last three months. Corporate insiders own 1.50% of the company's stock.

Analyst Ratings Changes

Several analysts have recently commented on the company. Needham & Company LLC restated a "buy" rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. HC Wainwright boosted their price objective on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a "buy" rating in a report on Monday, February 24th. Wolfe Research cut Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a report on Tuesday, November 12th. Scotiabank reduced their price target on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a "sector outperform" rating for the company in a research report on Friday, February 14th. Finally, StockNews.com downgraded shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, January 9th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $304.26.

Alnylam Pharmaceuticals Trading Down 0.4 %

NASDAQ:ALNY traded down $1.10 during mid-day trading on Thursday, reaching $248.13. 570,720 shares of the company's stock traded hands, compared to its average volume of 791,198. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The company has a 50 day moving average price of $254.46 and a 200-day moving average price of $261.81. The firm has a market capitalization of $32.12 billion, a price-to-earnings ratio of -114.35 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). On average, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.